Cargando…

Progress in multiple myeloma

Detalles Bibliográficos
Autores principales:	Munker, Reinhold, Monohan, Gregory
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2019
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755787/ https://www.ncbi.nlm.nih.gov/pubmed/31496521 http://dx.doi.org/10.4103/ijmr.IJMR_770_19

Ejemplares similares

Panobinostat and Multiple Myeloma in 2018
por: Yee, Andrew J., et al.
Publicado: (2018)

Treatment-Associated Acute Lymphoblastic Leukemia Following Autologous Hematopoietic Stem Cell Transplant and Lenalidomide Maintenance in Patients With Multiple Myeloma
por: Crosby, James, et al.
Publicado: (2022)

Abducens Nerve Palsy as Initial Presentation of Multiple Myeloma and Intracranial Plasmacytoma
por: Ibekwe, Elochukwu, et al.
Publicado: (2018)

Reimagining diversity in multiple myeloma clinical trials
por: Habr, Dany, et al.
Publicado: (2022)

Influence of gut microbiome on multiple myeloma: friend or foe?
por: Ahmed, Nausheen, et al.
Publicado: (2020)

Minimal residual disease in multiple myeloma: are we there yet?
por: Devarakonda, Srinivas, et al.
Publicado: (2020)

A new hope for patients suffering from multiple myeloma
por: Yu, Jinhua, et al.
Publicado: (2013)

Clinical characteristics and survival of patients with IgD multiple myeloma
por: Li, Yi, et al.
Publicado: (2021)

CT103A, a forward step in multiple myeloma immunotherapies
por: Xu, Jie, et al.
Publicado: (2021)

Proptosis with hemiplegia: Unusual presentation of multiple myeloma
por: Ghosh, K
Publicado: (2018)

Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models
por: Hu, Jinsong, et al.
Publicado: (2012)

Monoclonal Antibodies and Multiple Myeloma: All in All It's Just Another Brick in the Wall?
por: Musto, Pellegrino
Publicado: (2018)

Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine
por: Zátopková, Martina, et al.
Publicado: (2022)

Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast
por: Landgren, Ola, et al.
Publicado: (2023)

PPFIBP1 activates NF-κB signaling to enhance chemoresistance of multiple myeloma
por: Deng, Yi, et al.
Publicado: (2023)

Is aggressive treatment of smoldering myeloma the path to curing myeloma?
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

Survival from multiple myeloma in England and Wales up to 2001
por: Schey, S
Publicado: (2008)

Comment on: AI-supported modified risk staging for multiple myeloma cancer useful in real-world scenario
por: Khalil, Rania M., et al.
Publicado: (2021)

Supping with the Devil: Belief and the Imaginary World of Multiple Myeloma Therapies Invented by the Institute for Clinical and Economic Review
por: Langley, Paul C
Publicado: (2021)

Current perspectives on interethnic variability in multiple myeloma: Single cell technology, population pharmacogenetics and molecular signal transduction
por: Gandhi, Manav, et al.
Publicado: (2022)

MYC dysregulation in the progression of multiple myeloma
por: Misund, K, et al.
Publicado: (2019)

Pathophysiological Underpinnings of Multiple Myeloma Progression
por: Jagannath, Sungar
Publicado: (2008)

Pharmacologic Ascorbate in Myeloma Treatment: Doses Matter
por: Violet, Pierre-Christian, et al.
Publicado: (2017)

CAR-T cell therapy in myeloma: hopes and hurdles
por: Harousseau, Jean Luc
Publicado: (2023)

Bone Marrow Microenvironment in Multiple Myeloma Progression
por: Manier, S., et al.
Publicado: (2012)

Genomic patterns of progression in smoldering multiple myeloma
por: Bolli, Niccolò, et al.
Publicado: (2018)

Involvement of Alarmins in the Pathogenesis and Progression of Multiple Myeloma
por: Murdaca, Giuseppe, et al.
Publicado: (2021)

The Role of Epigenetics in the Development and Progression of Multiple Myeloma
por: Ismail, Nor Hayati, et al.
Publicado: (2022)

COVID-19 and Diagnostic Testing for SARS-CoV-2 by RT-qPCR—Facts and Fallacies
por: Bustin, Stephen, et al.
Publicado: (2021)

Clinical challenges: Myeloma and concomitant type 2 diabetes
por: Ali, Mohamed Ahmed, et al.
Publicado: (2013)

SNaPshot as a Valuable Option for the Identification of Mutations in Myeloma
por: Moreaux, Jerome
Publicado: (2014)

Supportive Care in Hematology
por: Hiemenz, John, et al.
Publicado: (2007)

Avid Xpress Pro for Windows and Macintosh
por: Monohan, James
Publicado: (2004)

Knowledge Is Power, but Is Ignorance Bliss? Optimising Conversations About Disease Progression in Multiple Sclerosis
por: Vermersch, Patrick, et al.
Publicado: (2019)

Progress in the identification of gene mutations involved in multiple myeloma
por: Hu, Ying, et al.
Publicado: (2019)

The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression
por: García-Ortiz, Almudena, et al.
Publicado: (2021)

Renal cell carcinoma and plasma cell myeloma: Coincidence or true association?
por: Mubarak, Muhammed
Publicado: (2014)

Revisiting checkpoint inhibitors for myeloma: maintenance after stem cell transplant
por: Meermeier, Erin W., et al.
Publicado: (2023)

Mesenchymal Stem Cell-derived Neural Progenitor Cells in Progressive Multiple Sclerosis: Great Expectations
por: Baldassari, Laura E., et al.
Publicado: (2018)

Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression
por: Maiso, Patricia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2vhfj8frkjbqe7cp265ps26jdm